NEOP News Neoprobe Introduces Bluetooth Wireless Probe
DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative
oncology and cardiovascular surgical and diagnostic products, today
announced that it introduced a new gamma detection probe at the American
College of Surgeons 92nd Annual Clinical
Congress meeting in Chicago. The new probe uses Bluetooth®
wireless technology to communicate gamma radiation counts to the Company’s
neo2000® control
unit. The wireless probe eliminates cumbersome cables that can
complicate the surgical field and provides the surgeon with operative
field flexibility. The new probe is designed to be used with all
existing models of the Company’s neo2000
system (Models 2000, 2100 and 2200). The wireless probe will be
available with either a straight or angled detection tip. The neo2000
line of gamma detection systems are widely used by cancer surgeons in a
procedure called Sentinel Lymph Node Biopsy (SLNB) or Intraoperative
Lymphatic Mapping (ILM).
David Bupp, Neoprobe’s President and CEO,
said, “We are excited by this new addition to
our neo2000 gamma detection product line. We believe the introduction of
a family of wireless gamma detection probes will offer the surgeon all
of the advantages of a cordless instrument using state of the art
Bluetooth technology coupled with the already easy-to-use features of
our existing neo2000 control unit. The new wireless probes, along with
the family of gamma detection probes that will continue to be offered,
will only improve our position as the market leader in gamma detection
and thus our market prospects. Because the Bluetooth probe will be
usable with our existing installed base of neo2000 system control units,
we believe our current customers as well as those considering the
purchase of a gamma detection system will be pleased. We expect the
first commercial shipments of the probe will occur during the fourth
quarter of 2006. The Bluetooth probes, coupled with our clinical
development program for the lymphatic tissue tracing agent Lymphoseek®,demonstrate Neoprobe’s commitment to
assist physicians in providing state of the art treatment for cancer
patients.”
About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and
improving patient outcome by meeting the critical intraoperative
diagnostic information needs of physicians and therapeutic treatment
needs of patients. Neoprobe currently markets the neo2000®
line of gamma detection systems that are widely used by cancer surgeons
and is commercializing the Quantix®
line of blood flow measurement products developed by its subsidiary,
Cardiosonix Ltd. In addition, Neoprobe holds significant interests in
the development of related biomedical systems and radiopharmaceutical
agents including Lymphoseek®
and RIGScan® CR.
Neoprobe’s subsidiary, Cira Biosciences,
Inc., is also advancing a patient-specific cellular therapy technology
platform called ACT. Neoprobe’s strategy is
to deliver superior growth and shareholder return by maximizing its
strong position in gamma detection technologies and diversifying into
new, synergistic biomedical markets through continued investment and
selective acquisitions. www.neoprobe.com
Bluetooth is a registered trademark of Bluetooth Sig, Inc.
